Pasithea Therapeutics Corp. to Present at the Benzinga Healthcare Small Cap Conference

Rhea-AI Summary

Pasithea Therapeutics Corp. (Nasdaq: KTTA) has announced that CEO Dr. Tiago Reis Marques will present at the Benzinga Healthcare Small Cap Conference on September 30, 2021, at 10:10 AM ET. The live presentation will be available via webcast and archived for 30 days on the company's website. Pasithea focuses on developing treatments for psychiatric and neurological disorders, targeting pathophysiology to improve efficacy and tolerability compared to conventional therapies. The company also provides business support services for anti-depression clinics in the UK and the US.

MIAMI BEACH, Fla., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that Dr. Tiago Reis Marques, Chief Executive Officer, will present at the Benzinga Healthcare Small Cap Conference as follows:

Date:		Thursday, September 30, 2021
Time:		10:10AM ET
Webcast Link:		https://www.benzinga.com/events/small-cap/healthcare/

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.pasithea.com, under the Investors section.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Its biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders, with the goal of developing new pharmacological agents that display significant advantages over conventional therapies with respect to efficacy and tolerability.

The Company’s secondary operations focus on providing business support services to anti-depression clinics in the United Kingdom and in the United States. The Company’s operations in the United Kingdom will involve providing business support services to registered healthcare providers who will assess patients, and if appropriate, administer intravenous infusions of ketamine, and the Company’s operations in the United States will involve providing business support services to entities that furnish similar services.

Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
E: tiago@pasithea.com

Pasithea Therapeutics Corp. Investor Relations
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

When is Pasithea Therapeutics presenting at the Benzinga Healthcare Small Cap Conference?

Pasithea Therapeutics will present on September 30, 2021, at 10:10 AM ET.

What is the focus of Pasithea Therapeutics Corp.?

Pasithea Therapeutics focuses on research and discovery of treatments for psychiatric and neurological disorders.

Where can I watch Pasithea's presentation?

The presentation can be viewed via webcast on Pasithea's website and will be archived for 30 days.

What are Pasithea's secondary operations?

Pasithea's secondary operations provide business support services to anti-depression clinics in the UK and the US.

What is the stock symbol for Pasithea Therapeutics?

The stock symbols are KTTA and KTTAW.